Omalizumab Efficacy, Drug Survival and Clinical and Serological Biomarkers in Chronic Inducible Urticaria
DOI:
https://doi.org/10.2340/actadv.v106.adv-2026-0875Keywords:
omalizumab, drug survival, discontinuation, chronic inducible urticaria, biomarkerAbstract
Chronic inducible urticaria is treated with offlabel omalizumab in antihistamine-refractory cases, although real-world evidence on its long-term efficacy, drug survival and predictive biomarkers is limited. The aim was to evaluate the real-world efficacy and long-term drug survival of omalizumab in chronic inducible urticaria and to identify clinical and serological predictors of response and persistence. This retrospective, multicentre study included 144 patients with isolated chronic inducible urticaria treated with omalizumab. At 6 months, 73% of patients achieved complete or good disease control. Solar urticaria showed a higher rate of complete control (69%), with a significantly higher rate than symptomatic dermographism (32%; p=0.0246). Most patients were fast responders (83%) and 26% required updosing. Higher body mass index was associated with lower complete control [odds ratio (OR) 0.92; p=0.049] and a greater likelihood of dose escalation (OR 1.11; p=0.019). Overall drug survival was 95%, 87.5% and 72.4% at 1, 2 and 5 years, respectively. Discontinuation occurred in 33% of patients, primarily due to remission (50%). Exploratory analyses did not identify robust predictors of cause-specific discontinuation. In conclusion, omalizumab is effective and well tolerated in chronic inducible urticaria, providing sustained control and long-term drug survival; however, baseline clinical and serum biomarkers did not predict treatment response or drug survival.
Downloads
References
Zuberbier T, Ansari ZA, Abdul Latiff AH, Abuzakouk MM, Agcaoili‐De Jesus MS, Agondi RC, et al. The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. Allergy 2026; 81: 2582–2632.
Weller K, Podder I, Salman A, Gimenez-Arnau AM, Neisinger S, Altrichter S. Clinical Evaluation and Outcome Measures of Chronic Spontaneous Urticaria and Chronic Inducible Urticaria. J Allergy Clin Immunol Pract 2025; 13: 2229–2241.
Muñoz M, Kiefer LA, Pereira MP, Bizjak M, Maurer M. New insights into chronic inducible urticaria. Curr Allergy Asthma Rep 2024; 24: 457–469.
Kaplan AP, Garofalo J, Sigler R, Hauber T. Idiopathic cold urticaria: in vitro demonstration of histamine release upon challenge of skin biopsies. N Engl J Med 1981; 305: 1074–1077.
Murphy GM, Zollman PE, Greaves MW, Winkelmann RK. Symptomatic dermographism (factitious urticaria)--passive transfer experiments from human to monkey. Br J Dermatol 1987; 116: 801–804.
Giménez-Arnau AM, Ribas-Llauradó C, Mohammad-Porras N, Deza G, Pujol RM, Gimeno R. IgE and high-affinity IgE receptor in chronic inducible urticaria, pathogenic, and management relevance. Clin Transl Allergy 2022; 12: e12117.
Kulthanan K, Church MK, Grekowitz EM, Hawro T, Kiefer LA, Munprom K, et al. Evidence for histamine release in chronic inducible urticaria - A systematic review. Front Immunol 2022; 13: 901851.
Gastaminza G, Azofra J, Nunez-Cordoba JM, Baeza ML, Echechipía S, Gaig P, et al. Efficacy and Safety of Omalizumab (Xolair) for Cholinergic Urticaria in Patients Unresponsive to a Double Dose of Antihistamines: A Randomized Mixed Double-Blind and Open-Label Placebo-Controlled Clinical Trial. J Allergy Clin Immunol Pract 2019; 7: 1599–1609.
Maurer M, Schütz A, Weller K, Schoepke N, Peveling-Oberhag A, Staubach P, et al. Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial. J Allergy Clin Immunol 2017; 140: 870–873.
Metz M, Schütz A, Weller K, Gorczyza M, Zimmer S, Staubach P, et al. Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial. J Allergy Clin Immunol 2017; 140: 864–867.
Litovsky J, Hacard F, Tétart F, Boccon-Gibod I, Soria A, Staumont-Sallé D, et al. Omalizumab Drug Survival in Chronic Urticaria: A Retrospective Multicentric French Study. J Allergy Clin Immunol Pract 2023; 11: 3752–3762.
Yu M, Terhorst‐Molawi D, Altrichter S, Hawro T, Chen Y, Liu B, et al. Omalizumab in chronic inducible urticaria: A real‐life study of efficacy, safety, predictors of treatment outcome and time to response. Clin Experimental Allergy 2021; 51: 730–734.
Can PK, Salman A, Hoşgören‐Tekin S, Kocatürk E. Effectiveness of Omalizumab in Patients with Chronic Inducible Urticaria: real‐life experience from two UCARE centres. Acad Dermatol Venereol 2021; 35: e679–e682.
Exposito-Serrano V, Curto-Barredo L, Aguilera Peiro P, Gómez Armayones S, Serra-Baldrich E, Spertino J, et al. Omalizumab for the treatment of chronic inducible urticaria in 80 patients. Br J Dermatol 2021; 184: 167–168.
Ghazanfar MN, Sand C, Thomsen SF. Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients. Br J Dermatol 2016; 175: 404–406.
Kocatürk E, Can PK, Akbas PE, Copur M, Degirmentepe EN, Kızıltac K, et al. Management of chronic inducible urticaria according to the guidelines: A prospective controlled study. J Dermatol Sci 2017; 87: 60–69.
Buters TP, van der Velden WAC, Abdisalaam I, van Maaren MS, van Doorn MBA. Effectiveness and tolerability of personalized omalizumab treatment in patients with chronic inducible urticaria. J Allergy Clin Immunol Pract 2021; 9: 3227–3229.
Fialek M, Dezoteux F, Le Moing A, Karimova E, Ramdane N, Pape E, et al. Omalizumab in chronic inducible urticaria: A retrospective, real-life study. Ann Dermatol Venereol 2021; 148: 262–265.
Jeong SH, Lim DJ, Chang SE, Kim KH, Kim KJ, Park EJ. Omalizumab on Chronic Spontaneous Urticaria and Chronic Inducible Urticaria: A Real-World Study of Efficacy and Predictors of Treatment Outcome. J Korean Med Sci 2022; 37: e211.
Metz M, Ohanyan T, Church MK, Maurer M. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. J Dermatol Sci 2014; 73: 57–62.
Metz M, Ohanyan T, Church MK, Maurer M. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria. JAMA Dermatol 2014; 150: 288–290.
Soegiharto R, Alizadeh Aghdam M, Sørensen JA, van Lindonk E, Bulut Demir F, Mohammad Porras N, et al. Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE study. Allergy 2025; 80: 489–499.
Spertino J, Curto Barredo L, Rozas Muñoz E, Figueras Nart I, Gimenez Arnau A, Serra Baldrich E, et al. Algorithm for Treatment of Chronic Spontaneous Urticaria with Omalizumab. Actas Dermosifiliogr (Engl Ed) 2018; 109: 771–776.
Pesqué D, Ciudad A, Andrades E, Soto D, Gimeno R, Pujol RM, et al. Solar Urticaria: An Ambispective Study in a Long-term Follow-up Cohort with Emphasis on Therapeutic Predictors and Outcomes. Acta Derm Venereol 2024; 104: adv25576.
Bizjak M, Košnik M. Key differences between chronic inducible and spontaneous urticaria. Front Allergy 2024; 5: 1487831.
Brás R, Costa C, Limão R, Caldeira LE, Paulino M, Pedro E. Omalizumab in Chronic Spontaneous Urticaria (CSU): Real-Life Experience in Dose/Interval Adjustments and Treatment Discontinuation. J Allergy Clin Immunol Pract 2023; 11: 2392–2402.
Curto-Barredo L, Spertino J, Figueras-Nart I, Expósito-Serrano V, Guilabert A, Melé-Ninot G, et al. Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria. Br J Dermatol 2018; 179: 210–212.
Gimenez-Arnau AM, Salman A, Podder I. Biomarkers to predict therapeutic response in chronic spontaneous urticaria: a review. European Journal of Dermatology 2024; 34: 3–12.
Zhang DG, Nielsen M, Sørensen JA, Naassan S, Vestergaard C, Kocatürk E, et al. Omalizumab dosing patterns and drug survival in adult patients with chronic spontaneous urticaria. Acad Dermatol Venereol 2025; 39: 1796–1805.
Soegiharto R, Alizadeh Aghdam M, Sørensen JA, van Lindonk E, Bulut Demir F, Porras NM, et al. Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for Discontinuation. JAMA Dermatol 2024; 160: 927–935.
Magerl M, Altrichter S, Borzova E, Giménez-Arnau A, Grattan CEH, Lawlor F, et al. The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy 2016; 71: 780–802.
Aydoğdu CT, Alataş ET, Pektaş SD, Yürekli A, Daşgın D, Chakmakchi A, et al. Biomarkers in chronic spontaneous urticaria for omalizumab drug survival: a retrospective analysis. Clin Exp Dermatol 2025; 51: 110–111.
Hasal E, Bulbul Baskan E, Yazici S, Aydogan K, Saricaoglu H. Factors Related to Omalizumab Drug Survival and Treatment Responses in Chronic Urticaria. Int Arch Allergy Immunol 2022; 183: 1198–1208.
Published
How to Cite
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
